Literature DB >> 34342209

The Italian Society for Rheumatology recommendations for the management of axial spondyloarthritis.

M Manara1, I Prevete2, A Marchesoni3, S D'Angelo4, A Cauli5, A Zanetti6, A Ariani7, A Bortoluzzi8, S Parisi9, C A Scirè10, N Ughi11.   

Abstract

Over the last few years, the landscape of treatments for axial spondyloarthritis (SpA) has been rapidly evolving, urging international scientific societies to draft or update existing clinical practice guidelines (CPGs) on the management of axial SpA. The Italian Society for Rheumatology (SIR) committed to provide revised and adapted evidence- and expert-based recommendations for the management of patients with axial SpA in Italy. A systematic approach to the adaptation of existing CPGs - the ADAPTE methodology - was adopted to obtain updated recommendations suitable for the Italian context. A systematic literature search was performed in Medline and Embase databases to find international CPGs and consensus statements with recommendations for the management of axial SpA published in the previous five years. A working group composed of rheumatologists with proven experience in the management of axial SpA and methodologists identified the key research questions which guided study selection and data extraction. Guideline quality was assessed using the Appraisal of Guidelines Research and Evaluation (AGREE) II tool. The Italian recommendations were developed by endorsing or adapting and rewording some existing recommendations. The draft of the recommendations was sent to a multidisciplinary group of external reviewers for comment and rating. Six original CPGs were selected and used to create this SIR CPG, which includes a final set of 14 recommendations covering the management of patients with axial SpA across the following domains: assessment, pharmacological and non-pharmacological treatment, and follow-up. The dissemination and implementation of these SIR recommendations are expected to support an evidencebased clinical approach to the management of patients with axial SpA in Italy.

Entities:  

Year:  2021        PMID: 34342209     DOI: 10.4081/reumatismo.2021.1367

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  2 in total

1.  Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.

Authors:  Simone Parisi; Andrea Becciolini; Maria Chiara Ditto; Davide Rozza; Anna Zanetti; Angela Laganà; Clara Lisa Peroni; Chiara Centanaro Di Vittorio; Rosanna Degiovanni; Cristina Realmuto; Carlo Alberto Scirè; Marta Priora; Eleonora Di Donato; Daniele Santilli; Flavio Mozzani; Gianluca Lucchini; Alarico Ariani; Lucia Gardelli; Francesco Girelli; Eugenio Arrigoni; Ilaria Platè; Elena Bravi; Marino Paroli; Rosalba Caccavale; Carlo Salvarani; Gilda Sandri; Federica Lumetti; Alessandro Volpe; Antonio Marchetta; Enrico Fusaro
Journal:  J Clin Med       Date:  2022-01-26       Impact factor: 4.241

2.  Residual Disease in Patients with Axial Spondyloarthritis: A Post-Hoc Analysis of the QUASAR Study.

Authors:  Salvatore D'Angelo; Carlo Salvarani; Francesca Marando; Giuliana Gualberti; Lucia Novelli; Giacomo Curradi; Giovanni Tripepi; Annalisa Pitino; Roberta Ramonda; Antonio Marchesoni
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.